Daily Roundup

CAT.ASX BOT.ASX EML.ASX ROC.ASX ARX.ASX

A Day of Breakthroughs: Sports Tech, Pharma, and Retail Tech Shine

Catapult Sports Unveils Ambitious Growth Plans Catapult Sports Ltd has set its sights high, revealing its FY26 Analyst Day presentation. The key focus is on growing the average contract value (ACV) per pro team, which the company believes is critical to delivering on its ambitious goals. While the financial information provided is purely illustrative and not intended as guidance, Catapult believes it could potentially increase ACV from an initial $20k to $100-150k through strategic initiatives like land with P&H, upsell features, and cross-selling new solutions. Investors will be eager to see how the company executes on this plan.

Botanix Renegotiates API Supply Deal, Strengthens Financial Position Botanix Pharmaceuticals Limited has successfully renegotiated its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical Co., Ltd. The revised deal defers upcoming API purchases to December 2027 and December 2028, with no purchases required before the end of 2027. This move is expected to bolster Botanix's financial position as it pursues growth plans for its Sofdra product. Additionally, the company is working to establish an additional API supplier for its Sofpironium Bromide, aiming to de-risk the supply chain and potentially reduce costs by 25-40%.

EML Appoints New CEO, Navigates Australian Regulatory Landscape EML Payments Ltd has appointed Adam Olding as its new Chief Executive Officer, effective immediately. This change reflects the company's progress on its EML2.0 transformation program and is intended to support the next phase of execution across regions and functions. In a separate update, EML's subsidiary EPSL is progressing an application to the Australian Prudential Regulation Authority (APRA) for a banking license. EPSL has also been advised to obtain an ADI guarantee for its stored value liabilities by April 2026, as it works with regulators to determine the best path forward.

RocketBoots Secures Activation Contract with Major Retailer RocketBoots Limited has executed a significant Activation Contract with a tier-one multinational retailer, marking a key milestone in the deployment and revenue generation phase of their previously announced SaaS agreement. The ~A$3.3 million contract will cover the services required to activate and deploy RocketBoots' AI-driven loss prevention platform across approximately 40% of the customer's global store network. This not only provides near-term implementation revenue but also sets the stage for long-term recurring SaaS revenue as the rollout progresses.

AROA Completes Successful Symphony Wound Care Trial AROA Biosurgery Limited has announced the completion of its randomised controlled trial (RCT) for Symphony, its Cellular, Acellular and Matrix-like Product (CAMP) designed for chronic, complex wounds. Preliminary findings indicate that the trial met its primary endpoint, with more diabetic foot ulcers healing within the 12-week study period when treated with Symphony compared to standard of care. These results are expected to support Symphony's clinical adoption and future reimbursement in the US market.